Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2020

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

Résumé

Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated in hematopoietic cancers. STAT3 and STAT5 are common targets for different tyrosine kinase oncogenes (TKOs). In addition, STAT3 and STAT5 proteins were shown to contain activating mutations in some rare but aggressive leukemias/lymphomas. Both proteins also contribute to drug resistance in hematopoietic malignancies and are now well recognized as major targets in cancer treatment. The development of inhibitors targeting STAT3 and STAT5 has been the subject of intense investigations during the last decade. This review summarizes the current knowledge of oncogenic STAT3 and STAT5 functions in hematopoietic cancers as well as advances in preclinical and clinical development of pharmacological inhibitors.

Domaines

Cancer Chimie
Fichier principal
Vignette du fichier
cancers-12-00240.pdf (2.65 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-02459040 , version 1 (13-11-2020)

Licence

Paternité

Identifiants

Citer

Marie Brachet-Botineau, Marion Polomski, Heidi Neubauer, Ludovic Juen, Damien Hédou, et al.. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers, 2020, 12 (1), pp.240. ⟨10.3390/cancers12010240⟩. ⟨hal-02459040⟩
106 Consultations
65 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More